医学
贫血
肾脏疾病
促红细胞生成素
红细胞生成
透析
血红蛋白
内科学
肾
海西定
缺氧诱导因子
生物化学
化学
基因
作者
Nan Chen,Chuanming Hao,Xiaomei Peng,Hongli Lin,Aiping Yin,Hao Li,Ye Tao,Xinling Liang,Zhengrong Liu,Changying Xing,Jianghua Chen,Liulin Luo,Li Zuo,Yunhua Liao,Bi‐Cheng Liu,Robert Leong,Chunrong Wang,Cameron Liu,Thomas B. Neff,Lynda A. Szczech,Kin-Hung Peony Yu
标识
DOI:10.1056/nejmoa1813599
摘要
Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI